170 related articles for article (PubMed ID: 36155293)
1. Clinical features and outcomes of opsoclonus myoclonus ataxia syndrome.
Yıldırım M; Öncel İ; Bektaş Ö; Tanalı G; Şahin S; Kutluk T; Teber S; Anlar B
Eur J Paediatr Neurol; 2022 Nov; 41():19-26. PubMed ID: 36155293
[TBL] [Abstract][Full Text] [Related]
2. Late cognitive and adaptive outcomes of patients with neuroblastoma-associated opsoclonus-myoclonus-ataxia-syndrome: A report from the Children's Oncology Group.
Kumar P; Willard VW; Embry L; Naranjo A; LaBarre B; Matthay KK; de Alarcon PA
Pediatr Blood Cancer; 2024 Jul; 71(7):e31039. PubMed ID: 38689540
[TBL] [Abstract][Full Text] [Related]
3. [Clinical and prognostic analysis of opsoclonus-myoclonus-ataxia syndrome in children].
Zhou J; Zhuo XW; Jin M; Duan C; Zhang WH; Ren CH; Gong S; Tian XJ; Ding CH; Ren XT; Li JW
Zhonghua Er Ke Za Zhi; 2024 Mar; 62(3):256-261. PubMed ID: 38378288
[No Abstract] [Full Text] [Related]
4. Treatment and revaccination of children with paraneoplastic opsoclonus-myoclonus-ataxia syndrome and neuroblastoma: The Memorial Sloan Kettering experience.
Patel A; Fischer C; Lin YC; Basu EM; Kushner BH; De Braganca K; Khakoo Y
Pediatr Blood Cancer; 2020 Aug; 67(8):e28319. PubMed ID: 32543116
[TBL] [Abstract][Full Text] [Related]
5. Five Years Follow-up of Opsoclonus-Myoclonus-Ataxia Syndrome-Associated Neurogenic Tumors in Children.
Aktekin EH; Gezer HÖ; Yazıcı N; Erol İ; Erbay A; Sarıalioğlu F
Neuropediatrics; 2024 Feb; 55(1):57-62. PubMed ID: 37019145
[TBL] [Abstract][Full Text] [Related]
6. Successful use of tacrolimus for treatment-refractory neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome: A case series.
Delap S; Shah N; Kuns O; Franklin B; Skeens MA
Pediatr Blood Cancer; 2024 Apr; 71(4):e30903. PubMed ID: 38321586
[TBL] [Abstract][Full Text] [Related]
7. A rare clinical presentation of COVID 19: opsoclonus-myoclonus ataxia syndrome.
Altunsoy A; Kemirtlek N; Araz H; Dirik EB; Akıncı E
J Infect Dev Ctries; 2024 Feb; 18(2):188-194. PubMed ID: 38484346
[TBL] [Abstract][Full Text] [Related]
8. Neuroblastic Tumor Recurrence Associated With Opsoclonus Myoclonus Ataxia Syndrome Relapse a Decade After Initial Resection and Treatments.
Bacchus MK; Anderson DS; Berko ER; States LJ; Bagatell R; Hopkins SE; Batra V
J Pediatr Hematol Oncol; 2023 Apr; 45(3):152-154. PubMed ID: 36897628
[TBL] [Abstract][Full Text] [Related]
9. Postinfectious SARS-CoV-2 Opsoclonus-Myoclonus-Ataxia Syndrome.
Nelson JL; Blume GM; Bansal SK; Kaufman JR; Woods FR; Zhang X; Kattah JC
J Neuroophthalmol; 2022 Jun; 42(2):251-255. PubMed ID: 34974489
[TBL] [Abstract][Full Text] [Related]
10. Pediatric opsoclonus-myoclonus-ataxia syndrome: Experience from a tertiary care university hospital.
Huddar A; Bindu PS; Nagappa M; Bharath RD; Sinha S; Mathuranath PS; Taly AB
Neurol India; 2018; 66(5):1332-1337. PubMed ID: 30232999
[TBL] [Abstract][Full Text] [Related]
11. Rituximab and intravenous immunoglobulins for relapsing postinfectious opsoclonus-myoclonus syndrome.
Leen WG; Weemaes CM; Verbeek MM; Willemsen MA; Rotteveel JJ
Pediatr Neurol; 2008 Sep; 39(3):213-7. PubMed ID: 18725071
[TBL] [Abstract][Full Text] [Related]
12. Opsoclonus-Myoclonus Syndrome: A New Era of Improved Prognosis?
Galstyan A; Wilbur C; Selby K; Hukin J
Pediatr Neurol; 2017 Jul; 72():65-69. PubMed ID: 28479124
[TBL] [Abstract][Full Text] [Related]
13. Benign paraspinal ganglioneuroma with paraneoplastic opsoclonus myoclonus syndrome.
Prabaharan H; Chandrasekaran S; Shetty N; Nayak K P
BMJ Case Rep; 2024 Feb; 17(2):. PubMed ID: 38417946
[TBL] [Abstract][Full Text] [Related]
14. Opsoclonus-myoclonus syndrome associated with a nasopharyngeal tumor in an adult: a case report.
Taib BG; Kinshuck AJ; Milburn-McNulty P; Fratalia L; Forsyth L; Husband D; Jones TM; Jacob A
J Med Case Rep; 2015 Jun; 9():128. PubMed ID: 26033370
[TBL] [Abstract][Full Text] [Related]
15. Surgical considerations for neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome: a series of 14 patients from a single institution.
Johnston WR; Hwang R; Mattei P
Pediatr Surg Int; 2022 Feb; 38(2):249-255. PubMed ID: 34549330
[TBL] [Abstract][Full Text] [Related]
16. Response to rituximab and prednisolone for opsoclonus-myoclonus-ataxia syndrome in a child with ganglioneuroblastoma.
Corapcioglu F; Mutlu H; Kara B; Inan N; Akansel G; Gürbüz Y; Topcu S
Pediatr Hematol Oncol; 2008 Dec; 25(8):756-61. PubMed ID: 19065442
[TBL] [Abstract][Full Text] [Related]
17. Neuroblastoma With Opsoclonus-Myoclonus-Ataxia Syndrome: Role of Chemotherapy in the Management: Experience From a Tertiary Care Center in a Resource-limited Setting.
Anand S; Agarwala S; Jain V; Bakhshi S; Dhua A; Gulati S; Seth R; Srinivas M; Jana M; Kandasamy D; Bhatnagar V
J Pediatr Hematol Oncol; 2021 Oct; 43(7):e924-e929. PubMed ID: 33769388
[TBL] [Abstract][Full Text] [Related]
18. Opsoclonus-myoclonus syndrome following influenza a infection.
Morita A; Ishihara M; Kamei S; Ishikawa H
Intern Med; 2012; 51(17):2429-31. PubMed ID: 22975562
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Responsiveness to Reduced-Dose Rituximab in Corticotropin/Intravenous Immunoglobulin/Rituximab Combination Immunotherapy for Opsoclonus-Myoclonus Syndrome.
Pranzatelli MR; Tate ED; McGee NR; MacArthur CA
Pediatr Neurol; 2018 Aug; 85():71-75. PubMed ID: 30197220
[TBL] [Abstract][Full Text] [Related]
20. Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.
Burke MJ; Cohn SL
Pediatr Blood Cancer; 2008 Mar; 50(3):679-80. PubMed ID: 16900484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
